Lippis Daniel J. 4
4 · Edwards Lifesciences Corp · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Lippis Daniel J.
CVP, TAVR
Transactions
- Exercise/Conversion
Common Stock
2026-01-09$59.26/sh+1,019$60,383→ 23,020.91 total - Sale
Common Stock
2026-01-09$85.70/sh−1,019$87,332→ 22,001.91 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2026-01-09−1,019→ 4,076 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (1,019 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.